News
MDXG
7.70
+1.18%
0.09
MiMedx Group (MDXG) Receives a Buy from Northland Securities
MiMedx Group has an analyst consensus of Strong Buy, with a price target of $12.25. Northland Securities analyst Carl Byrnes has reiterated a Buy rating on the stock. The company’s shares closed yesterday at $7.61. The stock has a corporate insider sentiment of negative.
TipRanks · 10h ago
Analysts Conflicted on These Healthcare Names: Cellectar Biosciences (CLRB), MiMedx Group (MDXG) and Marinus (MRNS)
TipRanks · 11h ago
MiMedx falls as FDA reaffirms position on Axiofill
Seeking Alpha · 1d ago
MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit
MiMedx Group says its Axiofill product doesn't meet requirements for a certain classification. The company has filed a lawsuit in Georgia federal court challenging the FDA's determination. MiMedx says it will continue to market the product in the meantime. The FDA says the company's product does not meet the requirements.
Dow Jones · 1d ago
*MiMedx Group Reiterates Expectations for 2024 Net Sales Percentage Growth in the Low Double Digits >MDXG
Dow Jones · 1d ago
Weekly Report: what happened at MDXG last week (0318-0322)?
Weekly Report · 3d ago
Northland Securities Keeps Their Buy Rating on MiMedx Group (MDXG)
Analyst Carl Byrnes maintains a Buy rating on MiMedx Group (MDXG) with a price target of $12.00. The company has a one-year high of $9.27 and a low of $3.08. The corporate insider sentiment is negative on the stock.
TipRanks · 03/21 12:25
TELA Bio launches Liquifix surgical devices in the U.S.
Healthcare TELA Bio launches Liquifix surgical devices in the U.S. Liquifix FIX8 and Liquifix Precision are approved by the FDA for mesh fixation of groin hernias. The company also announced an agreement to sell distribution rights to its wound care product to MiMedx Group.
Seeking Alpha · 03/21 11:59
Analysts Conflicted on These Healthcare Names: Diamedica Therapeutics (DMAC), Design Therapeutics (DSGN) and MiMedx Group (MDXG)
TipRanks · 03/20 12:50
TELA Bio Announces Sale Of Distribution Rights Related To NIVIS Fibrillar Collagen Pack
NASDAQ · 03/20 11:50
TELA Bio Sells Distribution Rights to Wound-Care Product to Mimedx
TELA Bio has sold its distribution rights related to the NIVIS Fibrillar Collagen Pack to Mimedx Group. The collagen matrix is indicated for the management of wounds and to control minor bleeding. The company will make an initial $5 million payment.
Dow Jones · 03/20 11:27
Weekly Report: what happened at MDXG last week (0311-0315)?
Weekly Report · 03/18 09:53
Weekly Report: what happened at MDXG last week (0304-0308)?
Weekly Report · 03/11 09:52
MiMedx Group Initiated at Buy by Lake Street
Dow Jones · 03/07 16:13
MiMedx Group Price Target Announced at $12.00/Share by Lake Street
Dow Jones · 03/07 16:13
Lake Street Initiates Coverage On MiMedx Group with Buy Rating, Announces Price Target of $12
Benzinga · 03/07 16:02
MiMedx Group Bolsters Board with Two New Directors
TipRanks · 03/04 13:22
Press Release: MIMEDX Announces Appointment of Two New Independent Directors
MIMEDX Announces Appointment of Two New Independent Directors. Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. The Board of directors unanimously agreed to expand its size to eleven directors. Both women bring extensive and relevant experience across the healthcare industry.
Dow Jones · 03/04 13:00
Weekly Report: what happened at MDXG last week (0226-0301)?
Weekly Report · 03/04 09:53
Mizuho Maintains Buy Rating for MiMedx Group: Here's What You Need To Know
Shares of MiMedx Group are trading up 0.98% over the last 24 hours. Mizuho has maintained its Buy rating and raised its price target from $13.00 to $14.00. The company develops and markets regenerative biomaterial products and bioimplants.
Benzinga · 03/01 17:00
More
Webull provides a variety of real-time MDXG stock news. You can receive the latest news about Mimedx Group Inc through multiple platforms. This information may help you make smarter investment decisions.
About MDXG
MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.